Securities code: 300347 securities abbreviation: Hangzhou Tigermed Consulting Co.Ltd(300347) announcement code (2022) No. 004
Hangzhou Tigermed Consulting Co.Ltd(300347)
Announcement of resolutions of the 21st Meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and shall be jointly and severally liable for false records, misleading statements or major omissions in the announcement.
The 21st Meeting of the 4th board of directors of Hangzhou Tigermed Consulting Co.Ltd(300347) (hereinafter referred to as "the company") was held in the conference room on the 19th floor, building 8, No. 19, Jugong Road, Binjiang District, Hangzhou on February 11, 2022. This meeting was held in the form of on-site and communication voting. The notice of the meeting was sent to all directors by telephone and e-mail on February 10, 2022. There are 7 directors who should attend the meeting and 7 directors who actually attend the meeting. The meeting was presided over by Mr. Ye Xiaoping, chairman of the company. The convening and procedures of this meeting meet the requirements of relevant laws, regulations and the articles of association, and the meeting is legal and effective.
After deliberation by the directors present at the meeting, the following resolutions were adopted by voting:
1、 The proposal on repurchase of shares of the company was deliberated and passed one by one.
The company plans to repurchase shares with its own funds or self raised funds. The total amount of shares repurchased shall not be less than RMB 250 million and not more than RMB 500 million. The price of shares repurchased shall not exceed RMB 120.00/share. This part of shares repurchased will be used as follow-up equity incentive plan or employee stock ownership plan. The term of this share repurchase is 12 months from the date when the board of directors deliberates and approves the share repurchase plan. Through the formulation of the share repurchase plan, the firm confidence of the company in the long-term intrinsic value is reflected, so that investors have a clearer understanding of the company's long-term intrinsic value, enhance investors' investment confidence in the company, and promote the reasonable return of the company's stock market price to the company's long-term intrinsic value.
The independent directors of the company expressed their independent opinions on this proposal.
See Hangzhou Tigermed Consulting Co.Ltd(300347) announcement on share repurchase scheme of the company disclosed at the same time on the information disclosure website designated by the China Securities Regulatory Commission on the gem for details.
1. Purpose and purpose of share repurchase
Voting results: 7 in favor, 0 against and 0 abstention
2. Ways of repurchasing shares
Voting results: 7 in favor, 0 against and 0 abstention
3. Price or price range and pricing principle of repurchased shares
Voting results: 7 in favor, 0 against and 0 abstention
4. Total amount and source of funds for share repurchase
Voting results: 7 in favor, 0 against and 0 abstention
5. Type, quantity and proportion of repurchased shares in total share capital
Voting results: 7 in favor, 0 against and 0 abstention
6. Implementation period of share repurchase
Voting results: 7 in favor, 0 against and 0 abstention
7. Validity of resolutions
Voting results: 7 in favor, 0 against and 0 abstention
8. Specific authorization for handling the share repurchase
Voting results: 7 in favor, 0 against and 0 abstention
It is hereby announced.
Hangzhou Tigermed Consulting Co.Ltd(300347) board of directors
February 14, 2002
